LONDON DAILY ARCHIVE

GlaxoSmithKline Reportedly Pursues £7 Billion Acquisition of US Cancer Drug Developer Nuvalent

The British pharmaceutical group is said to be in advanced discussions to acquire the American oncology specialist, a deal that would significantly expand its precision cancer treatment portfolio and deepen consolidation across the biotechnology sector.

09 June 2026 · 10:32 UTC